+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 1 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating BMS-986368, a FAAHMAGL inhibitor, for its effects on agitation in people with Alzheimers disease. This Phase 2, randomized, double-blind, placebo-controlled study aims to assess the efficacy, safety, and tolerability of this oral medication in participants aged 55 to 90 years who meet specific diagnostic and agitation criteria. Participants will be randomly assigned to one of three groups receiving either one of two doses of BMS-986368 or a placebo. The study medication is given orally on specified days during an 8-week treatment period. The trial includes a triple-blind design to ensure unbiased evaluation of outcomes. During the study, participants will be assessed for changes in agitation using tools like the Cohen-Mansfield Agitation Inventory CMAI and other behavioral scales up to Week 8. Safety will be monitored through adverse event tracking and laboratory tests up to 28 days after the last dose. Plasma levels of the study drug will be measured up to Week 14. The total participation lasts through the treatment and follow-up periods as defined by the study schedule.

Age: 55Years - 90YearsAll GendersPhase 2
77 locations